(Q34477827)

2 August 2017

title

Treatment of Wilson's disease with zinc: XV long-term follow-up studies (English)

1 reference

2 August 2017

Brewer GJ

1

1 reference

2 August 2017

Dick RD

2

1 reference

2 August 2017

Johnson VD

3

1 reference

2 August 2017

Brunberg JA

4

1 reference

2 August 2017

Kluin KJ

5

1 reference

2 August 2017

Fink JK

6

1 reference

2 August 2017

publication date

1 October 1998

1 reference

2 August 2017

published in

Translational Research

1 reference

2 August 2017

volume

132

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

264-278

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

2 August 2017

1 reference

COPPER METABOLISM IN NORMAL SUBJECTS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Studies on copper metabolism. XIV. Radioactive copper studies in normal subjects and in patients with hepatolenticular degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Defective biliary excretion of copper in Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Abnormalities of the physiology of copper in Wilson's disease. 3. The excretion of copper

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Biliary excretion of copper in Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

The psychiatric presentations of Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Prevention of Wilson's Disease in Asymptomatic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Oral zinc in Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Oral zinc therapy for Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with zinc XII: dose regimen requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Initial therapy of patients with Wilson's disease with tetrathiomolybdate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Penicillamine may detoxify copper in Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Zinc supplements and serum lipids in young adult white males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Pregnancy in Penicillamine-Treated Patients with Wilson's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

Neonatal abnormalities associated with D-penicillamine treatment during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990039-7

10.1016/S0022-2143(98)90039-7

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference